Research programme: antibody therapeutics - Diversa/Merck
Alternative Names: Antibody therapeutics research programme - Diversa/MerckLatest Information Update: 19 Mar 2010
At a glance
- Originator Diversa; Merck & Co
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 04 Mar 2008 This programme is still in active development
- 14 Jan 2005 Preclinical trials in Undefined in USA (Parenteral)